Study #2016-0573
Strategic Alliance: Phase I adoptive cellular therapy trial with endogenous CD8+ T cells (ACTolog® IMA101) alone or in combination with atezolizumab in patients with relapsed and/or refractory solid cancers
MD Anderson Study Status
Not Accepting
Treatment Agent
Fludarabine, Cyclophosphamide, IMA101 product, Recombinant human interleukin-2, Diagnostic Test: IMADetect, Atezolizumab
Description
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cancer, Solid Tumor
Study phase:
Phase I
Physician name:
Apostolia Tsimberidou
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-934-6089
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.